In a recent episode of Tech Leaders Unplugged, Adam Watson, the CEO and co-founder of MeCo Diagnostics shared his journey into the world of healthcare technology and how it is revolutionizing breast cancer treatment through the use of technology and predictive testing.
The Birth of MeCo Diagnostics
Adam Watson's background in cancer biology led him to a groundbreaking discovery during his graduate work. He focused on understanding how cancer cells respond to stiffness, known as mechanical conditioning. This work laid the foundation for what would become MeCo Diagnostics. The key takeaway here is that breast tumors are stiffer than surrounding tissue, and this physical difference influences the behavior of cancer cells.
The Role of Software Engineering and Testing
Before delving further into MeCo Diagnostics, it's important to highlight the role of software engineering and testing in this healthcare innovation. Software and predictive algorithms play a pivotal role in analyzing data from patients' tumors to determine their responsiveness to antifibrotic therapy. The accuracy and reliability of these algorithms are paramount, as they guide treatment decisions that can significantly impact patients' lives.
MeCo Diagnostics: A Game-Changer
MeCo Diagnostics takes its name from mechanical conditioning, the phenomenon Adam Watson studied during his Ph.D. research. The concept behind MeCo is to understand how cancer cells respond to stiffness and then use this knowledge to improve breast cancer treatment. Breast cancer is one of the most prevalent cancers among women, making it a pressing public health concern.
The company's mission is clear: address the rising healthcare costs associated with breast cancer treatment. As costs continue to soar, finding innovative ways to lower expenses is imperative. MeCo's approach involves repurposing antifibrotic drugs, which can reduce tumor stiffness. By leveraging these existing drugs and identifying which patients will benefit from them, MeCo Diagnostics aims to make breast cancer treatment more affordable and accessible.
The Predictive Biomarker Test
At the heart of MeCo Diagnostics' solution is the predictive biomarker test. This test analyzes a patient's tumor tissue, examining over a thousand genes to create a MeCo score. This score predicts whether a patient is likely to respond favorably to antifibrotic therapy. The significance of this test cannot be overstated—it enables personalized treatment decisions, ensuring that patients receive the most effective therapy for their specific condition.
Market Strategy and Expansion
One of the key questions posed during the discussion was how MeCo Diagnostics plans to bring its innovative solution to market. While Adam mentioned that direct-to-consumer sales were not part of their strategy, their goal is to partner with companies specializing in clinical genomic services. These companies already have the infrastructure, connections with physicians, and the capacity to raise awareness among patients.
Lessons Learned from Entrepreneurship and Grants
Adam's journey as an entrepreneur offers valuable insights for those contemplating startup ventures. He emphasized that grant applications, although essential, are highly competitive. Even with groundbreaking ideas, securing grant funding can be challenging. This realization motivated him to explore alternative funding avenues and ultimately led to the birth of MeCo Diagnostics.
Patients Can Be at Ease
Adam Watson's work at MeCo Diagnostics showcases how technology, predictive testing, and innovative thinking can reshape the landscape of breast cancer treatment. The integration of software engineering and testing ensures the accuracy and reliability of predictive algorithms, driving more personalized and cost-effective treatment decisions. As MeCo Diagnostics moves forward, it has the potential to inspire further advancements in personalized medicine and the repurposing of existing drugs to benefit patients and address the rising costs of healthcare.
Check out the video podcast about this blog by clicking here
